Background illustration for clinical trials search

Paid Clinical Trials Murfreesboro

Discover 1,249 paid clinical trials in Murfreesboro, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
New

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

for
B-cell Lymphoma, Chronic Lymphocytic Leukemia,
Location: Nashville TN, Aurora CO, Eugene OR
Sponsor: Nurix Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07520006

Phase1, Phase2, Recruiting
New

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

for
B-cell Lymphoma, Chronic Lymphocytic Leukemia,
Location: Nashville TN, Macon GA, Indianapolis IN, Fort Wayne IN,
Sponsor: Nurix Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07516093

Phase3, Recruiting

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

for
Prostate Cancer
Location: Nashville TN, Atlanta GA, Cincinnati OH,
Sponsor: Amgen

Sex: Male

Age: 18+

Code: NCT04221542

Phase1, Recruiting

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

for
Solid Tumor, Adult, Metastatic Breast Cancer,
Location: Nashville TN, Indianapolis IN, St Louis MO,
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All

Age: 18+

Code: NCT06625775

Phase1, Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

for
Non-Small Cell Lung Cancer
Location: Nashville TN, Lexington KY, Memphis TN, Greenville SC,
Sponsor: Summit Therapeutics

Sex: All

Age: 18+

Code: NCT05899608

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

for
Recurrent or Metastatic Solid Tumors
Location: Nashville TN, Chattanooga TN, Germantown TN, Skokie IL,
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06330064

Phase1, Phase2, Recruiting

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

for
Non-small Cell Lung Cancer,
Location: Nashville TN, Birmingham AL, Peoria IL, Cleveland OH,
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All

Age: 18+

Code: NCT06343402

Phase1, Recruiting

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

for
Solid Tumors, Hematologic Malignancies
Location: Nashville TN, Omaha NE, Houston TX, Duarte CA
Sponsor: Incyte Corporation

Sex: All

Age: 18+

Code: NCT07195916

Phase1, Recruiting

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

for
Breast Cancer
Location: Nashville TN, Salem VA, Columbia MD, Norfolk VA,
Sponsor: SCRI Development Innovations, LLC

Sex: All

Age: 18+

Code: NCT05748834

Phase2, Recruiting

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

for
Advanced Solid Tumors, HER2 Mutation
Location: Nashville TN, Cleveland OH, Toronto, Houston TX,
Sponsor: Bayer

Sex: All

Age: 18+

Code: NCT06760819

Phase2, Recruiting

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

for
Ovarian Cancer, Solid Tumor
Location: Nashville TN, Denver CO, Grand Rapids MI, Fairfax VA,
Sponsor: OnCusp Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06234423

Phase1, Recruiting

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

for
Advanced Solid Tumor, Metastatic Solid Tumor
Location: Nashville TN, Denver CO, Durham NC, Fairfax VA,
Sponsor: Jazz Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06108050

Phase1, Recruiting

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

for
Melanoma, Cutaneous Malignant
Location: Nashville TN, Columbus OH, Chapel Hill NC, Chicago IL,
Sponsor: Immatics US, Inc.

Sex: All

Age: 18+

Code: NCT06743126

Phase3, Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for
Colorectal Neoplasms
Location: Nashville TN, Atlanta GA, Jonesboro AR, St Louis MO,
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06662786

Phase3, Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

for
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer,
Location: Nashville TN, Birmingham AL, Atlanta GA, Athens GA,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT06881784

Phase3, Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

for
Locally Advanced or Metastatic ER+ HER2- Breast Cancer,
Location: Nashville TN, Louisville KY, Edgewood KY, Conroe TX,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT04606446

Phase2, Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

for
Metastatic Melanoma, Unresectable Melanoma, Melanoma
Location: Nashville TN, Birmingham AL, Bartlett TN, Cincinnati OH,
Sponsor: Iovance Biotherapeutics, Inc.

Sex: All

Age: 18 - 70

Code: NCT05727904

Phase3, Recruiting

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

for
Limited Stage Small Cell Lung Cancer
Location: Nashville TN, Knoxville TN, Corbin KY, Louisville KY,
Sponsor: SCRI Development Innovations, LLC

Sex: All

Age: 18+

Code: NCT06773910

Phase2, Recruiting

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

for
Solid Tumors With HRAS Alterations,
Location: Nashville TN, Denver CO, St Louis MO, Columbus OH,
Sponsor: Kura Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06026410

Phase1, Recruiting

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

for
Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer,
Location: Nashville TN, Detroit MI, Fairfax VA, Sarasota FL,
Sponsor: Accent Therapeutics

Sex: All

Age: 18+

Code: NCT06799065

Phase1, Recruiting